Logo image of ALLR

ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis

NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD

1.01  -0.03 (-2.88%)

Premarket: 1.03 +0.02 (+1.98%)

Fundamental Rating

2

Taking everything into account, ALLR scores 2 out of 10 in our fundamental rating. ALLR was compared to 551 industry peers in the Biotechnology industry. The financial health of ALLR is average, but there are quite some concerns on its profitability. ALLR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ALLR had negative earnings in the past year.
ALLR had a negative operating cash flow in the past year.
ALLR had negative earnings in each of the past 5 years.
ALLR had a negative operating cash flow in each of the past 5 years.
ALLR Yearly Net Income VS EBIT VS OCF VS FCFALLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of ALLR (-117.80%) is worse than 79.85% of its industry peers.
With a Return On Equity value of -185.17%, ALLR is not doing good in the industry: 66.06% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -117.8%
ROE -185.17%
ROIC N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALLR Yearly ROA, ROE, ROICALLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ALLR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLR Yearly Profit, Operating, Gross MarginsALLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALLR has more shares outstanding
The number of shares outstanding for ALLR has been increased compared to 5 years ago.
The debt/assets ratio for ALLR has been reduced compared to a year ago.
ALLR Yearly Shares OutstandingALLR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALLR Yearly Total Debt VS Total AssetsALLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ALLR has an Altman-Z score of -8.31. This is a bad value and indicates that ALLR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.31, ALLR is doing worse than 69.69% of the companies in the same industry.
ALLR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.31
ROIC/WACCN/A
WACCN/A
ALLR Yearly LT Debt VS Equity VS FCFALLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ALLR has a Current Ratio of 2.75. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.75, ALLR is not doing good in the industry: 67.51% of the companies in the same industry are doing better.
A Quick Ratio of 2.75 indicates that ALLR has no problem at all paying its short term obligations.
ALLR has a Quick ratio of 2.75. This is in the lower half of the industry: ALLR underperforms 65.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 2.75
ALLR Yearly Current Assets VS Current LiabilitesALLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

1

3. Growth

3.1 Past

ALLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.83%, which is quite impressive.
EPS 1Y (TTM)97.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLR Yearly Revenue VS EstimatesALLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2M 4M 6M 8M
ALLR Yearly EPS VS EstimatesALLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -500K -1M -1.5M

1

4. Valuation

4.1 Price/Earnings Ratio

ALLR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLR Price Earnings VS Forward Price EarningsALLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLR Per share dataALLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K -80K -100K

4.3 Compensation for Growth

A more expensive valuation may be justified as ALLR's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.98%

0

5. Dividend

5.1 Amount

ALLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (8/6/2025, 8:08:17 PM)

Premarket: 1.03 +0.02 (+1.98%)

1.01

-0.03 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners0.61%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap15.23M
Analysts43.33
Price TargetN/A
Short Float %4.69%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-123690
EYN/A
EPS(NY)-47.86
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.8%
ROE -185.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 2.75
Altman-Z -8.31
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.89%
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.21%
OCF growth 3YN/A
OCF growth 5YN/A